Neurogene is focused on developing life-changing genetic medicines for patients and their families a
Location: United States, New York
Employees: 11-50
Phone: +1 866-507-8240
Total raised: $68.5M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.02.2019 | Series A | $68.5M | - |
Mentions in press and media 10
| Date | Title | Description |
| 30.09.2025 | Rett Syndrome Research Trust Expands Internal Team to Speed the Advancement of Genetic Medicine Cures for Rett Syndrome | The Rett Syndrome Research Trust (RSRT) is excited to announce a significant expansion of its research team, accelerating the organization's mission to find cures for Rett syndrome, a devastating neurological genetic disorder caused by muta... |
| 18.07.2023 | Univ. of Washington spinout Neoleukin Therapeutics merging with New York City startup | After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is now planning to merge with New York City-based Neurogene, a gene therapy startup.... |
| 19.05.2022 | Neurogene’s Gene Replacement Program is the Eighth Biopharmaceutical Company Program Facilitated by the Rett Syndrome Research Trust | “RSRT is dedicated to finding a cure for Rett syndrome, and we are excited to see the science continue to progress toward that vision,” said RSRT CEO Monica Coenraads, “My colleagues and I will do everything in our power to help the Rett pr... |
| 18.12.2020 | Daily funding roundup - Dec. 18th, 2020 | WorkWhile has raised $3.5M; MetaCX landed $7.5M; PostHog secured $12M; Foresight picks up $15M Walnut: Walnut is a New York-based codeless, customizable platform that's aiming to help sales reps to "own their successful sales demo expe... |
| 16.12.2020 | Neurogene Closes $115 Million Series B Financing | NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115 million Series B financing. The ... |
| 16.12.2020 | Neurogene Closes $115M in Series B | NEW YORK, NY, Neurogene has closed $115M in Series B funding led by EcoR1 Capital. >> Click here for more funding data on Neurogene >> To export Neurogene funding data to PDF and Excel, click here Neurogene has closed $11... |
| 20.02.2020 | The evolution of New York City as a bioinnovation hub highlighted in new report | Three years ago, in its inaugural report on the venture capital landscape, New York City Health Business Leaders calculated that 79 startups and growth stage companies received $703 million in 2017. To put that in a national perspective, St... |
| 12.02.2019 | Neurogene Raises $68.5 Million In Series A | NEW YORK--(BUSINESS WIRE)--Neurogene, Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced a $68.5 million Series A financing. Investors inc... |
| 12.02.2019 | Neurogene Raises $68.5M in Series A Financing | Neurogene, Inc., a NYC-based company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, raised $68.5m in Series A financing. Investors included Samsara BioCapital, EcorR1... |
| - | The evolution of New York City as a bioinnovation hub highlighted in new report | Three years ago, in its inaugural report on the venture capital landscape, New York City Health Business Leaders calculated that 79 startups and growth stage companies received $703 million in 2017. To put that in a national perspective, St... |